{"title":"Population-specific optimization of polygenic risk scores for breast cancer in East Asians","authors":"Shu-Hsuan Liu, Yu-Chun Wang, Yun-Jer Shieh, Hai-Feng Tan, Kuo-Jang Kao, Chih-Chiang Hung, Ming-Feng Hou, Chi-Cheng Huang, Ching-Hung Lin, An-Chieh Feng, Jeng-Fong Chiou, Chien-Hsiun Chen, Ling-Hui Li","doi":"10.1016/j.gimo.2026.104487","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Polygenic risk scores (PRS) have shown promise in predicting disease susceptibility, but their accuracy varies across populations due to the limited representation of non-European ancestries in genomic studies. While European-derived PRS demonstrate some transferability to Asian populations, optimizing these scores for specific populations remains crucial for improving risk prediction.</div></div><div><h3>Methods</h3><div>Using data from the Taiwan Precision Medicine Initiative (<em>n</em> = 46,422) and an external validation cohort (<em>n</em> = 891), we developed an approach to optimize European-derived PRS for breast cancer prediction in East Asians. Our method involved 2 key steps: (1) replacing European PRS variants with Asian-specific single nucleotide polymorphisms within the same linkage disequilibrium blocks (<em>r</em><sup>2</sup> > 0.8) and (2) incorporating additional population-specific variants. We validated this approach using both breast and prostate cancer data sets.</div></div><div><h3>Results</h3><div>The optimized PRS (PRS<sub>EUR_replace+TPMI</sub>) showed improved predictive performance compared with the original European PRS (PRS<sub>EUR</sub>) in our main cohort, with an increased area under the curve from 0.608 to 0.617 and odds ratios per SD from 1.47 (95% CI 1.36-1.60) to 1.51 (95% CI 1.39-1.63). Individuals in the top 5% of PRS<sub>EUR_replace+TPMI</sub> demonstrated a 2.09-fold increased risk of developing breast cancer compared with those in the 40<sup>th</sup> to 60<sup>th</sup> percentile. External validation confirmed enhanced performance, and similar improvements were observed when this method was applied to prostate cancer prediction.</div></div><div><h3>Conclusion</h3><div>Our study presents a practical approach for optimizing European-derived PRS in non-European populations, which is particularly beneficial for populations with limited genetic data. As genetic data collection expands in these populations, this approach may help reduce health care disparities in the implementation of precision medicine.</div></div>","PeriodicalId":100576,"journal":{"name":"Genetics in Medicine Open","volume":"4 ","pages":"Article 104487"},"PeriodicalIF":0.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetics in Medicine Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949774426009970","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Polygenic risk scores (PRS) have shown promise in predicting disease susceptibility, but their accuracy varies across populations due to the limited representation of non-European ancestries in genomic studies. While European-derived PRS demonstrate some transferability to Asian populations, optimizing these scores for specific populations remains crucial for improving risk prediction.
Methods
Using data from the Taiwan Precision Medicine Initiative (n = 46,422) and an external validation cohort (n = 891), we developed an approach to optimize European-derived PRS for breast cancer prediction in East Asians. Our method involved 2 key steps: (1) replacing European PRS variants with Asian-specific single nucleotide polymorphisms within the same linkage disequilibrium blocks (r2 > 0.8) and (2) incorporating additional population-specific variants. We validated this approach using both breast and prostate cancer data sets.
Results
The optimized PRS (PRSEUR_replace+TPMI) showed improved predictive performance compared with the original European PRS (PRSEUR) in our main cohort, with an increased area under the curve from 0.608 to 0.617 and odds ratios per SD from 1.47 (95% CI 1.36-1.60) to 1.51 (95% CI 1.39-1.63). Individuals in the top 5% of PRSEUR_replace+TPMI demonstrated a 2.09-fold increased risk of developing breast cancer compared with those in the 40th to 60th percentile. External validation confirmed enhanced performance, and similar improvements were observed when this method was applied to prostate cancer prediction.
Conclusion
Our study presents a practical approach for optimizing European-derived PRS in non-European populations, which is particularly beneficial for populations with limited genetic data. As genetic data collection expands in these populations, this approach may help reduce health care disparities in the implementation of precision medicine.